There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Aura Biosciences Inc (AURA – Research Report) ...

SpringWorks Therapeutics Inc (NASDAQ:SWTX) is set to release its Q4 2024 earnings on February 20, 2025. The consensus estimate for Q4 2024 revenue is $59.12 million, and the earnings are expected to ...

SpringWorks Therapeutics (NASDAQ:SWTX) jumped 10% in premarket trading after the firm reported its Q4 results and canceled ...

Achieved $61.5 million and $172.0 million in fourth quarter and full year 2024 OGSIVEO® (nirogacestat) U.S. net product ...

We recently published a list of the 10 Best Performing Healthcare Stocks So Far in 2025. In this article, we are going to ...

Wedbush increased their Q2 2025 earnings per share estimates for SpringWorks Therapeutics in a research report issued on Wednesday, February 12th. Wedbush analyst D. Nierengarten now expects that the ...

Stock analysts at HC Wainwright dropped their FY2024 earnings per share estimates for SpringWorks Therapeutics in a research note issued on Wednesday, February 12th. HC Wainwright analyst R. Burns now ...

This article summarizes the most significant insider buying and selling activities reported for Wednesday, February 12, 2025, ...

Islam Saqib, the Chief Executive Officer of SpringWorks Therapeutics, Inc. (NASDAQ:SWTX), sold 48,000 shares of the company's common stock on February 10, 2025. The sale comes as the stock trades near ...

Daniel Pichl, Chief People Officer at SpringWorks Therapeutics, Inc. (NASDAQ:SWTX), executed a series of stock transactions on February 10, 2025. Pichl sold a total of 29,750 shares of common stock, ...

Daniel Pichl, Chief People Officer at SpringWorks Therapeutics (NASDAQ:SWTX), has recently sold a significant portion of his holdings in the company. According to a Form 4 filing with the SEC, Pichl ...